Mild to moderate depression. Major depressive disorder, single episode
Conditions
Interventions
Intervention 1: Intervention group: Fluoxetine 10 mg, once a day (Abidi Pharmaceutical Company, Iran) will be prescribed for 4 weeks and then the patients will be received Deprofade saffron capsule 20
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Age 18-60 years Diabetes mellitus type 2 Mild to moderate depression Fasting blood sugar less than 170 mg/dl Body mass index between 18.5 to 40 Consent to participate in the study
Exclusion criteria
Exclusion criteria: Consumption of psychiatric drugs before the study Substance abuse Insulin consumption Uncontrolled diabetes (HbA1c above 8%) History of severe stress Pregnancy Lactation other psychiatric illnesses including anxiety disorders Previous history of depression Mental disability
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The severity of depression. Timepoint: Before and after intervention (the end of 8 week of treatment). Method of measurement: Measurement of severity of depression based on the Hamilton Rating Scale for Depression (HRSD) score.;Incidence of treatment-related complication. Timepoint: During the intervention every week until the end of 8 week of treatment. Method of measurement: Based on the evaluation of patients' symptoms at weekly visits and incidence of any side effects related to treatment such as dry mouth, sleep disorders, headaches, digestive problems, urinary problems, sexual function problems and etc. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasumeh Ebrahimilagha
Ahvaz University of Medical Sciences
Outcome results
None listed